Hosted by HealthpointCapital
Hosted by HealthpointCapital
KiriGenX is developing a category-defining orthopedic biotechnology platform designed to enable earlier repair of progressive rotator cuff disease. Its Kiri-SE™ platform combines mechanical repair with bioinductive collagen augmentation to create a new upstream surgical category in articular-sided partial-thickness tears, with expansion potential across the whole rotator cuff. KiriGenX is advancing toward FDA clearance and commercialization through a capital-efficient development strategy supported by layered IP, an advanced preclinical program, an 18-member Scientific Advisory Board of leading orthopedic surgeons and commercial-scale manufacturing infrastructure.
